Latest:
Minimal Residual Disease Testing for Patients with Chronic Lymphocytic Leukemia
Adaptive Biotechnologies OncLive Sponsored Content Q&A
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
John M. Pagel, MD, PhD, Swedish Cancer Institute
Latest:
Delivering Long-Term Results for Blood Cancer Patients
While great progress has been made in developing and delivering new treatment options for chronic lymphocytic leukemia, recognizing the chronic nature of the disease and being cognizant of side effects that can have a major impact on a patient’s quality of life remains an important responsibility.
John Marshall, MD, Georgetown University Lombardi Comprehensive Cancer Center
Latest:
Metastatic Colorectal Cancer: Ongoing Challenges and Future Directions in Care
Closing out their panel on metastatic colorectal cancer, expert oncologists consider ongoing challenges and future evolutions within the treatment landscape.
John Minna, MD
Latest:
Dr. Minna on Chemotherapy and Radiation Therapy for Lung Cancer
John Minna, MD, Max L. Thomas Distinguished Chair in Molecular Pulmonary Oncology, Sarah M. and Charles E. Seay Distinguished Chair in Cancer Research, Hamon Center for Therapeutic Oncology, Internal Medicine, Pharmacology, UT Southwestern Medical Center, discusses the roles that both chemotherapy and radiation therapy will continue to have in the treatment of lung cancer.
John Morris, MD
Latest:
Dr. Morris on Lymphopenia as a Predictor of Survival in CRT-Treated NSCLC
John Morris, MD, professor of Medicine, co-director, Comprehensive Lung Cancer Center, associate director, UCCI Translational Research and Director, Experimental Therapeutics, University of Cincinnatti, discusses lymphopenia as a predictor of survival in chemoradiation-treated non–small cell lung cancer.